A collaboration between Indianapolis-based Eli Lilly and Co. (NYSE: LLY) and Merck & Co. Inc. (NYSE: MRK) is growing. The deal involves studying the combination of Lilly’s LARTRUVO and KEYTRUDA in patients with advanced or metastatic soft tissue sarcoma who had been treated previously.
Lilly is the study’s sponsor. Lilly Oncology President Sue Mahony said "we look forward to further expanding our collaboration with Merck to include this combination study focused on advanced soft tissue sarcoma, a rare and difficult-to-treat disease with limited treatment options. This collaborative study builds on the exciting data we have seen with olaratumab and supports our focus on investigating the potential of rational combinations to enhance efficacy and change the standards of care for people with cancer."
Merck Research Laboratories Vice President Eric Rubin says "our collaboration with Lilly exemplifies our commitment to fully exploring combination regimens with KEYTRUDA to help arm physicians with the treatment tools they need to help their patients."
The companies have several studies already ongoing as part of previous agreements. The new study is slated to begin in the middle of the year.
You can connect to more about the partnership by clicking here.